Article Text

Download PDFPDF
Randomised controlled trial
Should metformin be preferred over insulin therapy in the management of gestational diabetes (GDM)?
  1. Shannon D Sullivan
  1. Department of Endocrinology & Metabolism, Medstar Washington Hospital Center, Washington, DC, USA
  1. Correspondence to Dr Shannon D Sullivan
    Department of Endocrinology & Metabolism, Medstar Washington Hospital Center, 110 Irving Street, NW Suite 2A-72, Washington, DC, 20010, USA; Shannon.D.Sullivan{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


In this ancillary study of the Metformin in Gestational Diabetes (MiG) Trial, a prospective, randomised, multicentre trial in New Zealand and Australia, the investigators compare several circulating markers of metabolic risk in women with gestational diabetes (GDM) and in the cord blood of their offspring, to determine the differences between those treated with metformin or insulin during pregnancy.


In 236 metformin-treated and 242 insulin-treated women, fasting glucose, lipids, triglycerides (TGs), high-density lipoprotein, low-density lipoprotein and C reactive protein (CRP) were measured at randomisation (20–33 weeks’ gestation), at 36 weeks and at 6–8 weeks postpartum, as well as in cord blood. Treatment-group differences …

View Full Text


  • Competing interests None.